Showing results (31-40 of 67) with videos related to
Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|May 11, 2020
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancerFrancesco Facchinetti, Ludovic Lacroix, Laura Mezquita, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven MalignanciesFrancesco Facchinetti, Yohann Loriot, Floriane Brayé, et al.European Journal of Cancer (Oxford, England : 1990)|June 22, 2026
Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohortCedric Pobel, Hassan Badreddine, Cristina Smolenschi, et al.Nature Genetics|December 8, 2025
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutationsCarla Tangermann, Avantika Ghosh, Martin Ziegler, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2019
Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System ProgressionMihaela Aldea, Lizza Hendriks, Laura Mezquita, et al.JTO Clinical and Research Reports|September 30, 2021
Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief ReportDiego Enrico, Ludovic Lacroix, Jeanne Chen, et al.Ebiomedicine|February 13, 2016
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung CancerRyohei Katayama, Takuya Sakashita, Noriko Yanagitani, et al.JCO Precision Oncology|October 31, 2022
Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine OncologyPatricia Martin-Romano, Laura Mezquita, Antoine Hollebecque, et al.The Journal of Liquid Biopsy|March 3, 2025
Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experienceClaudia Parisi, José Carlos Benitez, Hélène Lecourt, et al.Nature Communications|February 25, 2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancerHayato Mizuta, Koutaroh Okada, Mitsugu Araki, et al.Pageof 7